Anzeige
Mehr »
Montag, 29.09.2025 - Börsentäglich über 12.000 News
Seltene Ausgangslage: Unbekannter Kupfer-Explorer mit spekulativem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PF3G | ISIN: US21900C3088 | Ticker-Symbol: 19KA
Tradegate
29.09.25 | 20:16
10,300 Euro
+6,74 % +0,650
1-Jahres-Chart
CORMEDIX INC Chart 1 Jahr
5-Tage-Chart
CORMEDIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,95010,30020:27
9,95010,30020:27

Aktuelle News zur CORMEDIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:58CorMedix schließt Patientenrekrutierung für Phase-III-Studie zu Pilzinfektionen ab2
CORMEDIX Aktie jetzt für 0€ handeln
14:54CorMedix completes enrollment in phase III fungal infection study1
14:36CorMedix, Inc.: CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO51- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study...
► Artikel lesen
DiCRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?5
19.09.Insider Decision Making Waves At Cormedix: Gregory Scott Duncan Exercises Options, Realizing $45K9
18.09.Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?5
15.09.CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?5
12.09.Major Exercise Alert: Beth Zelnick Kaufman Exercises Options Worth $495K At Cormedix1
12.09.Strategic Sale: Elizabeth Hurlburt Decides To Exercise Options Worth $635K At Cormedix6
09.09.Analyst Expectations For Cormedix's Future6
09.09.CorMedix-Investment in Talphera schafft Pipeline-Optionalität - JMP bestätigt Rating9
09.09.CorMedix stock investment in Talphera adds pipeline optionality, JMP reiterates1
09.09.Talphera Announces $29 Mln Private Placement Led By CorMedix And Institutional Investors3
08.09.Talphera Secures Up To $29 Mln In Private Placement Led By CorMedix2
08.09.CorMedix, Inc.: CorMedix Announces Strategic Minority Investment in Talphera232BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...
► Artikel lesen
02.09.Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?6
02.09.CorMedix Inc. - 8-K, Current Report-
02.09.CorMedix, Inc.: CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team217- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue...
► Artikel lesen
08.08.CorMedix signs agreement to acquire Melinta for $300m7
07.08.CorMedix expands infectious disease portfolio with $300M acquisition of Melinta3
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1